A Trial of a New Therapy to Target the Redness and Scaling of Congenital Ichthyosis
THIS STUDY IS NOW CLOSED
This study has thus far identified that all evaluated ichthyosis subtypes (ARCI-lamellar ichthyosis (ARCI-LI), congenital ichthyosiform erythroderma (ARCI-CIE), epidermolytic ichthyosis (EI) and Netherton syndrome), were tightly linked to increases in the same arm of the immune system that is activated in psoriasis, a common skin issue characterized by skin redness and scaling. The initial trial phase is to test whether a new, commercially available psoriasis medication, which specifically targets the arm of the immune system that is overactive in ichthyosis, will reduce redness and scaling.
It is only open to adults 18 years and older, with one of the following conditions: ARCI-lamellar ichthyosis (LI), congenital ichthyosiform erythroderma (CIE), epidermolytic ichthyosis (EI) and Netherton syndrome. We will push for an extension to children if results are favorable. We encourage any FIRST members who are interested in participating in our year-long trial (to be held in Chicago and New York City) to contact us by email at email@example.com or by phone at 312-227-6486 for more information.